Elevated plasma transforming growth factor β1 levels predict the development of hypertension in normotensives: The 14-year follow-up study

American Journal of Hypertension

Volumn 30, Issue 8, 2017, Pages 808-814

  Nakao, Erika ^a   Adachi, Hisashi ^a   Enomoto, Mika ^a   Fukami, Ako ^a   Kumagai, Eita ^a   Nakamura, Sachiko ^a   Nohara, Yume ^a   Kono, Shoko ^a   Sakaue, Akiko ^a   Morikawa, Nagisa ^a   Tsuru, Tomoko ^a   Fukumoto, Yoshihiro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood pressure; Cytokine; Epidemiology; Hypertension; Hypertrophy; Transforming growth factor 1

Indexed keywords

ANTIHYPERTENSIVE AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; BODY MASS; CONFIDENCE INTERVAL; CONFOUNDING VARIABLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; JAPAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MIDDLE AGED; ODDS RATIO; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; BLOOD; DRINKING BEHAVIOR; ELECTROCARDIOGRAPHY; PREVALENCE; SMOKING;

AGED; ALCOHOL DRINKING; BLOOD PRESSURE; BODY MASS INDEX; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85026487931     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpx053     Document Type: Article

References (35)

1. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
2. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschler C, Laggner AN, Hirschl MM. Increased levels of transforming growth factor-beta1 in essential hypertension. Am J Hypertens 2002; 15: 207-211.
3. Bhola NE, Balko JM, Dugger TC, Kuba MG, Schez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013; 123: 1348-1358.
4. Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Mantzaris G, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGFbeta receptor I kinase. Cancer Res 2011; 71: 955-963.
5. Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology 2010; 52: 966-974.
6. Villarreal FJ, Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992; 262: H1861-H1866.
7. Takahashi N, Calderone A, Izzo NJ Jr, Mi TM, Marsh JD, Colucci WS. Hypertrophic stimuli induce transforming growth factorbeta 1 expression in rat ventricular myocytes. J Clin Invest 1994; 94: 1470-1476.
8. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-Term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273-279.
9. Laviades C, Varo N, Dz J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517-522.
10. Bobik A. Hypertension, transforming growth factor-beta, angiotensin II and kidney disease. J Hypertens 2004; 22: 1265-1267.
11. Esmatjes E, Flores L, Lario S, Clia J, Cases A, Igo P, Campistol JM. Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabetes Care 1999; 22: 1915-1916.
12. Peterson MC. Circulating transforming growth factor-β-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit. 2005; 11: RA229-RA232.
13. Fukami A, Adachi H, Hirai Y, Enomoto M, Otsuka M, Kumagai E, Nakamura S, Yoshimura A, Obuchi A, Nohara Y, Nakao E, Hori K, Fukumoto Y. Association of serum eicosapentaenoic acid to arachidonic acid ratio with microalbuminuria in a population of communitydwelling Japanese. Atherosclerosis 2015; 239: 577-582.
14. Obuchi A, Adachi H, Enomoto M, Fukami A, Kumagai E, Nakamura S, Yoshimura A, Nohara Y, Nakao E, Umeki Y, Fukumoto Y, Imaizumi T. High plasma fetuin-A levels are associated with metabolic syndrome among males but not females in a Japanese general population. Diabetes Res Clin Pract 2014; 106: 128-135.
15. Esaki E, Adachi H, Hirai Y, Yamagishi S, Kakuma T, Enomoto M, Fukami A, Kumagai E, Ohbu K, Obuchi A, Yoshimura A, Nakamura S, Nohara Y, Fujiyama T, Fukumoto Y, Imaizumi T. Serum vaspin levels are positively associated with carotid atherosclerosis in a general population. Atherosclerosis 2014; 233: 248-252.
16. Almendral JL, Shick V, Rosendorff C, Atlas SA. Association between transforming growth factor-beta(1) and left ventricular mass and diameter in hypertensive patients. J Am Soc Hypertens 2010; 4: 135-141.
17. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116-2123.
18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233-270.
19. Tanaka H, Oki T, Tabata T, Yamada H, Harada K, Kimura E, Oishi Y, Ishimoto T, Ito S. Losartan improves regional left ventricular systolic and diastolic function in patients with hypertension: accurate evaluation using a newly developed color-coded tissue doppler imaging technique. J Card Fail 2004; 10: 412-420.
20. Haramaki R, Tamaki K, Fujisawa M, Ikedo H, Haramaki N, Okuda S. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis 2001; 38: 1191-1198.
21. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, Hamaoki M, Kato H, Yazaki Y. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989; 159: 1435-1440.
22. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-188.
23. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002; 106: 130-135.
24. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005; 28: 483-490.
25. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109: 787-796.
26. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltageduration product. J Am Coll Cardiol 1992; 20: 1180-1186.
27. Nakayoshi T, Adachi H, Ohbu-Murayama K, Enomono M, Fukami A, Kumagai E, Nakamura S, Nohara Y, Nakao E, Sasaki K, Fukumoto Y. Plasma heat shock protein 27 is increased in renal dysfunction and habitual smoking in a Japanese general population. J Cardiol 2016; 67: 110-114.
28. Cucina A, Corvino V, Sapienza P, Borrelli V, Lucarelli M, Scarpa S, Strom R, Santoro-D'Angelo L, Cavallaro A. Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells. Biochem Biophys Res Commun 1999; 257: 306-312.
29. Shen Y, Rattan V, Sultana C, Kalra VK. Cigarette smoke condensateinduced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol 1996; 270: H1624-H1633.
30. Scaglione R, Argano C, Parrinello G, Colomba D, Di Chiara T, Ferrante A, Di Garbo V, Avellone G, Licata G. Relationship between transforming growth factor beta1 and progression of hypertensive renal disease. J Hum Hypertens 2002; 16: 641-645.
31. August P, Sharma V, Ding R, Schwartz JE, Suthanthiran M. Transforming growth factor beta and excess burden of renal disease. Trans Am Clin Climatol Assoc 2009; 120: 61-72.
32. Suthanthiran M, Gerber LM, Schwartz JE, Sharma VK, Medeiros M, Marion R, Pickering TG, August P. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int 2009; 76: 72-80.
33. Huang Y, Border WA, Noble NA. Perspectives on blockade of TGFbeta overexpression. Kidney Int 2006; 69: 1713-1714.
34. Villar AV, Cobo M, Llano M, Montalvo C, Gonzez-Vchez F, Mart-Dur R, Hurl-MA, Nistal JF. Plasma levels of transforming growth factor-beta1 reflect left ventricular remodeling in aortic stenosis. PLoS One 2009; 4: e8476.
35. Xu HY, Hou XW, Wang LF, Wang NF, Xu J. Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 2010; 335: 13-17.